Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
Compiles new knowledge on pathobiology of hematologic cancer
Gives comprehensive information on current treatments on malignant hematologic diseases
Written by international leaders on the field
In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. This book is well suited for hematology residents, fellows and hematology-oncology physicians, hematopathologist as well as basic research scientist in the area of hematologic malignancies.
Preface. Chapter 1: B-Cell Growth, Differentiation and Malignancies (Chih-Chi Andrew Hu and Jianguo Tao).- Chapter 2: Follicular Lymphoma: Recent advances (Alyssa Bouska,SharathKumar Bagvati, Javeed Iqbal, Basem M. William, Wing C. Chan).- Chapter 3: Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy (Chih-ChiAndrew Hu and Javier Pinilla-Ibarz).- Chapter 4: Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy (Kenneth H. Shain and William S Dalton).- Chapter 5: EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly (Jorge J. Castillo).- Chapter 6: HIV and Lymphoma (Lubomir Sokol and Brady Betran).-Chapter 7: Molecular Biology of Mantle Cell Lymphoma (Bijal Shah, Peter Martin , Jianguo Tao, and Eduardo M. Sotomayor),- Chapter 8:Pathogenesis of Non-Hodgkin Lymphoma Derived from Inflammatory, Autoimmune or Immunologic Disorders (Ling Zhang and Jianguo Tao).- Chapter 9:Pathogenesis of Non-Hodgkin Lymphoma Derived from Infection Diseases (Ling Zhang and Roger Klein).- Chapter 10: Hodgkin Lymphoma: From Molecular Pathogenesis to Targeted Therapy(Adam Jona, Arpad Illes, and Anas Younes).- Chapter 11: Myelodysplastic Syndromes (Grant E. Nybakken and Adam Bagg).- Chapter 12: Chronic Myeloproliferative Disorders: from Molecular Pathogenesis to Targeted Therapy (Richard AWalgren, Edited by Josef Prchal).- Chapter 13: Chronic Myeloid Leukemia (Kapil Bhalla, Celalettin Ustun, Warren Fiskus).- Chapter 14: Novel Targeted Therapeutics for Acute Myeloid Leukemia (Jeffrey Lancet and Vu Duong).- Chapter 15: Novel Targeted Therapeutics for Peripheral T-Cell Lymphoma (O Connor, Jain and Zain).- Chapter 16: Large Granular Lymphocyte Leukemia – From Molecular Pathogenesis to Targeted Therapy (ThomasLoughran Jr, Mithun Vinod Shah).- Chapter 17: Epigenetic Regulation and Therapy in Lymphoid Malignancies (Yizhuo Zhang, Shangi Gao, Haifeng Zhao).- Index.